MedPath

The effect of systemic antibiotics on post-surgical complications and patient-centered outomes in patients undergoing implant surgery with the guided bone regeneration and simultaneous sinus floor elevation.

Phase 4
Not yet recruiting
Conditions
The medical condition that the patients have in this trial is edentulism in a posterior maxillary quadrant of the mouth with a sinus pneumatisation/ decreased crestal bone heigh defect requiring augmentation and rehabilitation with 1-3 implants. We want to investigate the effect of amoxicillin after this procedure in terms of complications and patient-centered outcomes.
Registration Number
2025-521185-10-00
Lead Sponsor
Complutense University Of Madrid
Brief Summary

To evaluate the effect of systemic antibiotic administration on postsurgical complications, in patients undergoing oral implant therapy with simultaneous lateral approach sinus floor elevation and guided bone regeneration (GBR).

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised, recruitment pending
Sex
Not specified
Target Recruitment
30
Inclusion Criteria
  1. Medically healthy adult (ASA classification I-II), age # 21 years old 2. Non-smoker, previous smoker (quit # 5 years); light smoker with less than 10 cigarettes/ day 3. Not allergic to Amoxicillin/Penicillin antibiotics, NSAIDS or corn-starch 4. Edentulous spaces in the posterior maxilla in one or 2 posterior quadrants with an alveolar bone defect requiring sinus floor elevation and allowing implant placement of up to 3 dental implants and simultaneous GBR (residual crest height 3-5 mm; per implant site (Felice et al. 2012; Park et al. 2019). 5. Absence of signs of pathology of the sinus membrane and acute sinusitis requiring ongoing management
Exclusion Criteria

Medically compromised subjects (ASA classification III-V); General contraindications against implant treatment or augmentative procedures (e.g. immunodeficiency, advanced systemic diseases, corticosteroid medication); Those taking Bisphosphonates/anti-angiogenic/RANKL inhibitor medications or receiving local radio-therapy; Heavy smoker or previous heavy smoker (quit < 5 years; ≥ 10 cigarettes/day); Allergic to Amoxicillin or Penicillin antibiotics, NSAIDS and / or corn starch; Use of any form of antibiotics in the last 3 months or subjects requiring regular antibiotic prophylaxis prior to dental treatment; Pregnant or breast feeding. Self-declared intend to conceive (A pregnancy test will be performed for all female patients); Need for 2 stage sinus augmentation; Acute or unmanaged symptomatic sinusitis; Type 1 implant placement (immediate implant placement following extraction); Need for simultaneous soft tissue augmentation; Residual bone height of > 5mm; Subjects aged < 21 years old

Study & Design

Study Type
Not specified
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Patient Reported Outcome Measures (PROMs): Visual analogue scores VAS on the wound (pain, swelling, bruising (haematoma), bleeding) and discomfort of the sinuses (nosebleed, nasal congestion, rhinorrhea (excessive nasal discharge including posterior nasal drip), feeling of pressure, hyposmia (reduction in smell)

Patient Reported Outcome Measures (PROMs): Visual analogue scores VAS on the wound (pain, swelling, bruising (haematoma), bleeding) and discomfort of the sinuses (nosebleed, nasal congestion, rhinorrhea (excessive nasal discharge including posterior nasal drip), feeling of pressure, hyposmia (reduction in smell)

Secondary Outcome Measures
NameTimeMethod
Clinical recordings of post-surgical complications: flap closure/dehiscence, purulent discharge, swelling and implant stability and early implant loss.

Clinical recordings of post-surgical complications: flap closure/dehiscence, purulent discharge, swelling and implant stability and early implant loss.

Trial Locations

Locations (1)

Complutense University Of Madrid

🇪🇸

Madrid, Spain

Complutense University Of Madrid
🇪🇸Madrid, Spain
MARIANO SANZ
Site contact
913942021
marianosanz@odon.ucm.es

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.